Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases
Open Access
- 15 August 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (16) , 4859-4866
- https://doi.org/10.1158/1078-0432.ccr-06-0422
Abstract
We examined whether RNA expression of CD133, a surface molecule expressed on progenitors from hematopoietic and endothelial lineages, and CD146, a pan-endothelial marker, are increased in the blood of cancer patients and whether these factors correlate with patient characteristics and are predictive factors of survival. We developed a real-time quantification method (nuclear acid sequence-based amplification) to determine expression of CD146 and CD133 mRNA in the peripheral blood mononuclear cells of 131 progressive cancer patients, 37 healthy volunteers, and 5 patients who received granulocyte colony-stimulating factor. Overall survival and other clinicopathologic variables were obtained. Cox proportional hazards studies were done. We show that patients with metastatic disease have a significant increase in CD133 mRNA (P = 0.03), specifically patients with bone metastasis (P < 0.001). Cancer patients with high CD133 mRNA expression, using a defined cutoff value, show a decreased survival compared with patients with low or undetectable CD133 expression (21% versus 45% cumulative survival, respectively, after 20 months; P = 0.01). Among patients with metastasis to the bone, cumulative survival was 22%, compared with 61% for patients with high or low CD133 levels (P = 0.004). Multivariate analysis showed that CD133 expression is an independent predictor for overall survival in patients with bone metastases. CD146 mRNA was not increased in patients with cancer, nor did it correlate with clinical variables or survival. CD133, but not CD146, mRNA expression is increased in cancer patients with metastatic disease, specifically with bone metastasis. In addition, CD133 mRNA expression seems to be an independent prognostic factor for overall survival.Keywords
This publication has 43 references indexed in Scilit:
- Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid TumorsJournal of Clinical Oncology, 2006
- Differential CD146 Expression on Circulating Versus Tissue Endothelial Cells in Rectal Cancer Patients: Implications for Circulating Endothelial and Progenitor Cells As Biomarkers for Antiangiogenic TherapyJournal of Clinical Oncology, 2006
- Prospective Identification of Tumorigenic Prostate Cancer Stem CellsCancer Research, 2005
- Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activityBlood, 2005
- Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromesLeukemia & Lymphoma, 2005
- Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic ActivityClinical Cancer Research, 2005
- Circulating endothelial progenitor cells in multiple myeloma: implications and significanceBlood, 2005
- Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesisImplications for cellular surrogate marker analysis of antiangiogenesisCancer Cell, 2005
- Nasba Technology: Isothermal RNA Amplification in Qualitative and Quantitative DiagnosticsImmunological Investigations, 1997
- Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification ReactionsNature Biotechnology, 1993